Exenatide long-acting release - AstraZeneca

Drug Profile

Exenatide long-acting release - AstraZeneca

Alternative Names: Bydureon; Bydureon Pen; Byetta LAR; Exenatide extended-release for injectable suspension; Exenatide LAR; Exenatide once-weekly suspension; Ready to Use Exenatide Once Weekly

Latest Information Update: 17 Jun 2017

Price : $50

At a glance

  • Originator Amylin Pharmaceuticals
  • Developer AstraZeneca; Eli Lilly
  • Class Antihyperglycaemics; Obesity therapies; Peptides; Venoms
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 2 diabetes mellitus
  • Phase II Obesity

Most Recent Events

  • 24 Apr 2017 AstraZeneca completes a phase IIIb/IV EXSCEL trial in Type 2 diabetes mellitus in USA, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Czechia, Germany, Hong Kong, Hungary, Israel, Italy, South Korea, Latvia, Lithuania, Malaysia, Mexico, Netherlands, New Zealand, Philippines, Poland, Romania, Russia, Slovakia, South Africa, Spain, Taiwan, Thailand, Ukraine and United Kingdom (NCT01144338)
  • 11 Oct 2016 Exenatide long-acting release licensed to Hongkong Sansheng for commercialisation in China
  • 16 Sep 2016 Positive efficacy and adverse events data from the phase III DURATION-8 trial in Type-2 diabetes mellitus (Adjunctive treatment) released by AstraZeneca
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top